Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:2552:165-197.
doi: 10.1007/978-1-0716-2609-2_9.

Assessing and Engineering Antibody Stability Using Experimental and Computational Methods

Affiliations

Assessing and Engineering Antibody Stability Using Experimental and Computational Methods

Cheng Zhang et al. Methods Mol Biol. 2023.

Abstract

Engineering increased stability into antibodies can improve their developability. While a range of properties need to be optimized, thermal stability and aggregation are two key factors that affect the antibody yield, purity, and specificity throughout the development and manufacturing pipeline. Therefore, an ideal goal would be to apply protein engineering methods early-on, such as in parallel to affinity maturation, to screen out potential drug molecules with the desired conformational and colloidal stability. This chapter introduces our methods to computationally characterize an antibody Fab fragment, propose stabilizing variants, and then experimentally verify these predictions.

Keywords: Aggregation; Antibody; B-factor; Entropy; Fab; Molecular dynamics (Gromacs); Rosetta; Tm.

PubMed Disclaimer

Similar articles

References

    1. Grilo AL, Mantalaris A (2019) The increasingly human and profitable monoclonal antibody market. Trends Biotechnol 37:9–16 - DOI - PubMed
    1. Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs 7:9–14 - DOI - PubMed
    1. Wu X, Sereno AJ, Huang F et al (2015) Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 7:470–482 - DOI - PubMed - PMC
    1. Carter PJ, Lazar GA (2018) Next generation antibody drugs: pursuit of the “high-hanging fruit.”. Nat Rev Drug Discov 17:197–223 - DOI - PubMed
    1. Chiu ML, Gilliland GL (2016) Engineering antibody therapeutics. Curr Opin Struct Biol 38:163–173 - DOI - PubMed

Publication types

LinkOut - more resources